Goodwin Procter LLP advised Unum Therapeutics Inc on the deal.
Unum Therapeutics Inc completed the acquisition of Kiq LLC, a privately held, biotechnology company focused on the discovery and development of precision kinase inhibitors. The acquisition was structured as a stock-for-stock transaction whereby all of Kiq’s outstanding equity interests were exchanged for a combination of shares of Unum common stock and shares of newly created Series A preferred stock. The acquisition was approved by the Board of Directors of Unum and the equity holders of Kiq. The closing was not subject to the approval of Unum stockholders.
Based in Cambridge, MA, Unum Therapeutics is a biopharmaceutical company focused on developing a pipeline of novel therapies to treat cancer patients. Unum’s most advanced program, PLX9486, is a highly potent and selective KIT D816V inhibitor that is being developed to treat systemic mastocytosis and GIST patients.
The Goodwin team advising on the acquisition was led by Andrew Goodman (Picture), and included Nicole Daley, Tevia Pollard and Stephanie Dworkin.
Law Firms: Goodwin Procter;
Clients: Unum Therapeutics;